Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mizolastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 10/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 8/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 17/20 | 0.75 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mizolastine SCHEMBL5061 | 1.00 | HRH1 (1.00) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL29256081 | 0.99 | HRH1 (0.98) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL28266367 | 0.97 | HRH1 (0.95) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL4443891 | 0.85 | HRH1 (0.73) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL18597171 | 0.83 | HRH1 (0.74) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| Mizolastine SCHEMBL6273027 | 0.82 | HRH1 (0.84) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL12668369 | 0.82 | HRH1 (0.69) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL21984846 | 0.81 | HRH1 (0.69) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL12045361 | 0.81 | HRH1 (0.68) | HRH1KCNH2CHRM1ADRA2AHTR2B | |
| SCHEMBL18388464 | 0.81 | HRH1 (0.78) | HRH1KCNH2CHRM1ADRA2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| EP-3563885-B1 | ABSORBABLE IRON-BASED DEVICE | BIOTYX MEDICAL SHENZHEN CO LTD (CN) | 2023-01-25 | — | — | EP | claimed |
| US-20250327082-A1 | New C5a Binding Nucleic Acids | APTARION BIOTECH AG (DE) | 2025-10-23 | — | — | US | disclosed |
| EP-4633602-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | Nanexa AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312275-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| EP-4620474-A1 | METHOD OF TREATING A DISORDER WITH A C5A INHIBITOR | APTARION biotech AG (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-20250248497-A1 | MEDICATION TRANSPORT WALLET AND METHODS OF USE | UCB Biopharma SRL (BE) | 2025-08-07 | — | — | US | disclosed |
| EP-4536179-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | Nanexa AB (SE) | 2025-04-16 | — | — | EP | disclosed |
| EP-2152341-B2 | ATOMIZER IN THE FORM OF AN INHALER FOR MEDICAL AEROSOL THERAPY | BOEHRINGER INGELHEIM PHARMA (DE) | 2025-04-02 | — | — | EP | disclosed |
| WO-2022258988-A1 | NEW COMPOSITION COMPRISING IMMUNOMODULATORY DRUG | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258987-A1 | NEW FORMULATIONS COMPRISING AZACITIDINE | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022258985-A1 | NEW FORMULATIONS COMPRISING BIOLOGIC ACTIVE DRUGS | NANEXA AB (SE) | 2022-12-15 | — | — | WO | disclosed |
| US-11492625-B2 | C5a binding nucleic acids | APTARION BIOTECH AG (DE) | 2022-11-08 | — | — | US | disclosed |
| WO-2022228516-A1 | NASAL DROPS CONTAINING STEM CELL-DERIVED EXTRACELLULAR VESICLES AND USE THEREOF IN TREATMENT OF CEREBRAL NEUROVASCULAR DISEASES | 西比曼生物科技（上海）有限公司 | 2022-11-03 | — | — | WO | disclosed |
| CN-114762790-A | Carbon dioxide recovery system and method for operating carbon dioxide recovery system | 株式会社东芝 | 2022-07-19 | — | — | CN | disclosed |
| CN-110090530-B | Carbon dioxide recovery system and method for operating carbon dioxide recovery system | 株式会社东芝 | 2022-06-24 | — | — | CN | disclosed |
| US-11235277-B2 | Carbon dioxide capture system and method of operating carbon dioxide capture system | KABUSHIKI KAISHA TOSHIBA (JP) | 2022-02-01 | — | — | US | disclosed |